What is lawful, what is not, and where businesses get it wrong
Publication Article
Drafted by Elamine Lawyers
Australian legal update | Commonwealth and Victorian focus
Prepared 28 March 2026
| Executive summary This article provides a practical overview of the Australian legal position on importing, advertising and supplying peptides, with particular focus on Victorian regulatory exposure. It is intended as a general publication piece for business owners, clinic operators, wellness marketers and advisers, and should not be relied upon as legal advice for any specific transaction or proposed business model. |
Disclaimer
This publication is general information only. It is not legal advice. The regulatory position depends on the particular product, its classification, its intended use, the manner of advertising and supply, and the factual structure of the proposed operation. Specific advice should be obtained before importing, promoting or supplying any peptide product in Australia.
This article provides a practical overview of the Australian legal position on importing, advertising and supplying peptides, with a particular focus on Victorian regulatory risk. It is written for business owners, clinic operators, wellness marketers and advisers who need a commercially realistic view of what is lawful, what is not, and where the common compliance traps lie.
There is no shortage of confidence in the peptide market. There is, however, a shortage of caution.
Over the past few years, peptides have been marketed online as though they sit somewhere between supplements, wellness products and laboratory consumables. That is where many operators get themselves into trouble. In Australia, the legal position is not driven by branding language or clever disclaimers. It is driven by substance, intended use, mode of supply, advertising conduct and the applicable Commonwealth and State regulatory framework. If a product is being imported, promoted or supplied for human therapeutic use, the Therapeutic Goods Administration will look at the substance of the conduct, not the marketing spin attached to it.
For businesses in Victoria, there is a further layer. Even if an operator has considered Commonwealth therapeutic goods law, it must also consider the Victorian medicines and poisons regime, including licensing and permit requirements for possessing, manufacturing, wholesaling or otherwise dealing with scheduled substances. That dual regulatory exposure is where many otherwise commercially minded ventures come unstuck.
The starting point: Australia does not treat this as a casual consumer market
The first issue is classification. In Australia, therapeutic goods are regulated because they carry risk as well as potential benefit. As a general rule, therapeutic goods must be entered in the Australian Register of Therapeutic Goods before they can be lawfully supplied in, imported into or exported from Australia, unless an exemption, approval or authority applies. If a peptide product is being sold for therapeutic use in people, ARTG entry or another lawful pathway becomes central.
That matters because many peptide sellers proceed on a false premise. They assume that if the product was sourced overseas and is easy to buy online, it can be sold here with a sharper brand and a few disclaimers. That is not how the legislation works. In Australia, the regulatory burden sits heavily on the entity bringing the product into market. If an Australian business imports a therapeutic good for supply, it will ordinarily be treated as the sponsor, and that role carries regulatory responsibility for the product.
Why the sponsor concept matters
Businesses often underestimate the word sponsor. It sounds administrative. It is not. It is the point at which commercial enthusiasm meets legal responsibility.
From a risk-management perspective, the real question is not whether stock can be brought into Australia. The proper question is whether there is a lawful pathway to import and supply the product, and whether the business can stand behind its compliance position if the regulator asks questions. In many casual peptide ventures, the honest answer is no.
The Victorian position
For a Victorian operator, the analysis does not stop at the TGA. Victoria regulates medicines and poisons through its own statutory regime. Licences authorise manufacturing and wholesaling activities involving scheduled substances, while permits may authorise educational, research, industrial entities and health services to obtain them where required.
In commercial terms, that is where many lean start-up models fail. A founder may assume that an online store, imported stock and careful wording is enough. It is not enough if the product category and the conduct fall within both Commonwealth therapeutic goods regulation and Victorian licensing controls. This is not an area where improvisation is a sound operating model.
The advertising trap
One of the most common errors is to focus on supply while ignoring advertising. Certain therapeutic goods cannot be advertised to the general public, including prescription-only medicines and unapproved therapeutic goods. That means websites, social media posts, testimonials, paid partnerships, captions, hashtags and influencer arrangements can all create exposure.
The lesson is simple. A business can be in breach before any sale is completed. Promotional conduct itself can be enough to attract regulatory attention.
The research use only myth
This is the favourite workaround in the space, and it is usually the weakest. A seller will describe the product as research grade, for research use only or not for human consumption, while simultaneously publishing content that points squarely toward human outcomes such as anti-ageing, fat loss, vitality, muscle gain or metabolic benefit.
If the surrounding conduct shows a human therapeutic purpose, the disclaimer may do little more than prove that the supplier knew there was a problem. The law looks at the real position.
Diagram 1 – How regulators usually assess the conduct
| Product imported |
| How is it presented? |
| Laboratory-only, genuine non-human research context, controlled users |
| Wellness, anti-ageing, fitness or fat-loss messaging |
| Likely therapeutic representation -> TGA advertising, supply and import obligations engaged |
The personal importation scheme
The personal importation scheme is widely misunderstood. It allows individuals, in limited circumstances, to import certain therapeutic goods not entered on the ARTG for their own use or the use of an immediate family member, subject to the conditions of the scheme.
It is not a stepping stone to small-scale trading. It is not a lawful pilot program for a business. It is not a way to buy stock under one name and redistribute it through friends, gym contacts or private messaging. The moment resale enters the picture, the legal complexion changes sharply.
Table 1 – Do’s and don’ts for businesses
| Do | Why it is sensible | Don’t | Why it is dangerous |
| Obtain advice on whether the product is a therapeutic good and whether a lawful supply pathway exists | Classification and pathway are threshold issues under the TGA regime. | Assume overseas availability means Australian legality | Overseas sale does not determine Australian compliance status. |
| Assess whether the business will be treated as the sponsor | The sponsor carries core regulatory responsibility. | Pretend to be a mere intermediary while importing for supply | Substance prevails over form in the compliance analysis. |
| Review Victorian licensing and permit requirements if dealing with scheduled substances | State law may separately regulate possession, manufacture and wholesale activities. | Focus only on Commonwealth law | Victorian obligations may still be engaged. |
| Keep public-facing content strictly compliant | Advertising rules capture websites and social media. | Promote prescription-only or unapproved products to the public | This is prohibited and has led to enforcement action. |
| Keep personal importation separate from business activity | The scheme is limited to personal or immediate family use. | Resell personally imported goods | The scheme does not allow sale or supply to others. |
Table 2 – Legal versus illegal conduct comparison
| Scenario | Likely position |
| A patient imports a limited quantity for personal use with the required prescription and does not resell it | Potentially lawful under the personal importation scheme if all conditions are met. |
| A clinic markets peptide products online to the public with anti-ageing or performance claims | High risk of unlawful advertising if the products are prescription-only or unapproved therapeutic goods. |
| An online seller imports stock into Australia for commercial supply without a lawful market pathway | High risk. ARTG entry or another lawful pathway is generally required. |
| A Victorian wholesaler deals with scheduled substances without considering State licensing requirements | High risk under Victorian medicines and poisons controls. |
| A seller uses research use only labelling while clearly targeting human consumers | High risk. The disclaimer is unlikely to cure the underlying breach. |
Chart 1 – Relative exposure by business model
| Business model | Regulatory risk |
| Personal import for own use under scheme conditions | Low to moderate |
| Genuine institutional research supply in a controlled setting | Moderate |
| Private gym-network resale | Very high |
| Public online peptide store | Extreme |
| Clinic marketing prescription-only peptides to the public | Extreme |
The commercial reality
The market often speaks the language of optimisation, longevity and performance. The regulator speaks the language of supply, representation, importation and public protection. Those two vocabularies do not sit comfortably together.
Many peptide ventures are built backwards. The founder starts with demand, then finds a supplier, then builds a website, then adds disclaimers, then hopes the legal analysis can be patched in later. In regulated product categories, that sequencing is fundamentally unsound. Compliance is not a finishing touch. It is the gateway issue.
Table 3 – Governance checklist before launch
| Question | Why it matters |
| What exactly is the product, and how is it classified? | Classification drives the entire regulatory pathway. |
| Is ARTG entry required, or is another lawful pathway available? | Lawful supply generally depends on this question. |
| Who is the sponsor? | The sponsor bears key legal responsibility. |
| What claims will appear on the website, social media and sales materials? | Advertising rules apply broadly and are actively enforced. |
| Does Victorian licensing or permit regulation apply? | State law may independently regulate the operation. |
| Is the business trying to rely on personal importation or research use only language? | Those are common failure points, not reliable compliance strategies. |
Final observations
The legal position is not subtle. In Australia, peptides cannot be treated as though they occupy a regulatory grey zone simply because they are fashionable, science-adjacent or sold with sophisticated branding. If the conduct involves importing, promoting or supplying products for human therapeutic use, the TGA framework is engaged. If the operation in Victoria involves scheduled substances, State controls may be engaged as well.
The blunt commercial answer is this. For most informal operators, there is no safe shortcut. If a business is not prepared to build a genuinely compliant regulatory model from the ground up, it should assume that importing and selling peptides in Australia is legally hazardous and potentially unlawful. That is not fearmongering. It is simply the regulatory position as it presently stands.
Sources and reference material
• Therapeutic Goods Administration, Overview of supplying therapeutic goods in Australia.
• Therapeutic Goods Administration, Role of the sponsor.
• Therapeutic Goods Administration, Import and export guidance.
• Therapeutic Goods Administration, What can and cannot be advertised to the general public.
• Therapeutic Goods Administration, Advertising therapeutic goods on social media.
• Therapeutic Goods Administration, Personal importation scheme.
• Therapeutic Goods Administration, Compliance actions and outcomes, including court action.
• Victorian Department of Health, Licences and permits to possess and possibly supply scheduled substances.
• Victorian Department of Health, Drugs, poisons and controlled substances legislative framework.
Disclaimer: This publication is general information only and is not legal advice. Specific advice should be obtained on the facts of any proposed importation, advertising, supply arrangement or clinic model.
